The effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride in normal as well as diabetic rats was studied. In normal and streptozotocin induced diabetic rats the combination of glimepiride with piperine increased all the pharmacokinetic parameters, such as C max , AUC 0-n , AUC total , t ½, and MRT, and decreased the clearance, Vd, markedly as compared with the control group. In pharmacodynamic studies, the combination of glimepiride with piperine provided significant protection against the diabetes induced alterations in the biochemical parameters. In addition, the combination of glimepiride with piperine also improved the total antioxidant status significantly in diabetic rats compared with piperine and glimepiride treated groups. The results revealed that a combination of glimepiride with piperine led to the enhancement of the bioavailability of glimepiride by inhibiting the CYP2C9 enzyme, which suggested that piperine might be beneficial as an adjuvant to glimepiride in a proper dose, in diabetic patients.
A combination of herbal drugs (or isolated phytochemicals) is found to be beneficial in certain diseases when given along with conventional drugs. Glimepiride, a sulfonylurea used as an oral hypoglycemic agent, is widely used for the treatment of type 2 diabetes mellitus. The hypoglycemic effect of glimepiride was changed during co-administration with Carica papaya extract [1] , thus there is a need to study the interaction between glimepiride and other drugs to avoid adverse effects.
Piperine, obtained from the dried unripe fruits of Piper nigrum and P. longum (Piperaceae), is one of the main active ingredients of sugurd capsules and diabecon tablets, which are used for diabetic patients. It also has immunomodulatory activity [2] , and may relieve the symptoms of cataract blindness [3] . Thus, it is possible that piperine can be administered with oral hypoglycemic drugs concomitantly. There are several reports of the in vitro inhibition of CYP 450s, especially CYP3A4, CYP1A2, CYP2D6 [4] and CYP2C9 by piperine. Hence there is the possibility of the use of piperine for the metabolic inhibition of glimepiride, which is completely metabolized by CYP2C9 microsomal liver enzymes [5] .The aim of the present study was to investigate the effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride in normal and streptozotocin induced diabetic rats to study the synergistic effects of the concomitant treatment with these drugs.
From the pharmacokinetic study of normal and diabetic rats it was found that the C max of glimepiride was significantly increased in piperine-glimepiride (1.21, 1.69 times), AUC 0-n (1.16, 1.58 times), AUC total (1.20, 1.75 times), t 1/2 (1.42, 1.55 times), and MRT (1.09, 1.34 times), whereas the clearance and volume of distribution of glimepiride was decreased 0.89, 0.75 times in normal rats, and 0.49, 0.48 times in diabetic rats, when compared with the control group. Mean pharmacokinetic parameters of glimepiride in different groups of normal and diabetic rats is shown in Table 1 . The T max of glimepiride in both normal and diabetic groups was not altered by concurrent administration with piperine. In normal and STZinduced diabetic rats, combination of glimepiride with piperine led to a significant increase in pharmacokinetic parameters such as C max , AUC 0-n , AUC total , t 1/2 and MRT. The results are in agreement with earlier reports that piperine increases the bioavailability of vasicine, sparteine [6] , propranolol and theophylline [7] , and increases the plasma levels of coenzyme q10 [8] . This may be due to alteration in the metabolism of glimepiride either by enhancing absorption or by inhibiting CYP2C9 responsible for glimepiride metabolism. In piperine treated group there is no change in the T max of glimepiride in either normal or diabetic rats indicating that there is no alteration in the rate of absorption of glimepiride and the serum affinity of glimepiride for albumin is 99.5% bound. Acidic drugs can displace ionic binding of sulfonylureas from serum proteins to a far greater extent than the non-ionic bound glimepiride. This indicates that the decreased volume of distribution may not be due to displacement of glimepiride by piperine. As there are no plasma protein binding interactions between piperine and glimepiride, the decreased volume of distribution may be due to metabolic inhibition of glimepiride by piperine. The present investigations are in accordance with the earlier in vitro studies of piperine metabolic inhibition of CYP2C9 enzyme in human liver microsomes [9, 10] .
In pharmacodynamic study, the mean serum glucose level and percentage glucose reduction in the antihyperglycemic method of pretreated diabetic rats is shown in Table 2 . The data reveal that there is a maximum reduction of serum glucose level of 68.8% in piperine-glimepiride pretreated group, when compared with the standard (glimepiride, 53.9%) and piperine (51.1%) pretreated groups after six hours. The increase in hypoglycemic action by concomitant administration of glimepiride with piperine was greater in the diabetic rats than when the drugs were used singly and with the control group, which suggests the enhancement of glucose reduction capacity of glimepiride in diabetic rats along with piperine.
In sub acute study, there was a gradual diminution in the body weight of animals in diabetic control group. The piperine, piperineglimepiride and standard drug treated groups showed a gradual and significant (p < 0.01) increase in body weight from 7 days onwards. The increase in body weight was observed till the end of the study ( Figure 1A ). This reveals that these drugs do not have any effect on the degradation of depot fat to maintain body weight [11] .
The effect of piperine-glimepiride in reducing blood glucose levels was gradually increased and was at a maximum after 28 days (56.5%). The significant antihyperglycemic effect of piperineglimepiride in comparison with the standard drug, glimepiride (51.2%), and piperine alone (44.6%) pretreated groups was maintained at all time intervals of the study ( Figure 1B) . This phenomenon clearly indicates that these drugs, in combination, control the hyperglycemic state of type 2 diabetes more effectively than the drugs on their own. There was a significant effect (p < 0.01) of piperine-glimepiride in reducing serum GOT and GPT levels; this was maximum after 28 days (41.7% and 39.5%, respectively), and was greater than that of the standard drug, glimepiride (29.2%, 26.5%) and piperine alone (23.7%, 35.9%) ( Figure 1C, 1D ). This significant (p < 0.01) reduction in SGOT and SGPT levels further strengthens the antidiabetogenic effect of these drugs because increased gluconeogenesis and ketogenesis occur in diabetes, which may be due to high levels of SGOT and SGPT [12] .
The percent reductions in serum triglyceride and cholesterol levels were: for the piperine-glimepiride treated group 57.3% and 58.0%, for the standard group 51.4%, 55.8%, and for the piperine alone pretreated group 51.2%, 56.0% ( Figure 1E and 1F) . These results clearly indicate that these drugs in combination have more antihypertriglyceridemic and antihypercholesterolemic activity than the drugs used individually.
The significant effect (p < 0.01) of the piperine-glimepiride group on serum total protein levels was maximum after 28 days (72.8%) compared with those of the standard (52.0%) and piperine alone (68.2%) pretreated groups (Figure 2 ). This increased serum total protein level produced by these drugs explains the antidiabetogenic effect, as a reduction in protein level takes place in diabetes due to deficiency of insulin, which stimulates the uptake of aminoacids into muscle and increases protein synthesis [13] .
The significant effect (p < 0.01) of the piperine-glimepiride group on increasing serum insulin levels was maximum after 28 days (76.7%) compared with those of the glimepiride (55.4%) and piperine alone (54.1%) pretreated groups (Figure 3 ). This significant increase in serum insulin levels indicates that piperine might have exhibited an antihyperglycemic effect like glimepiride, i.e. by insulin secretogogue activity [14] .
The serum total antioxidant status of different pretreated groups in diabetic rats is shown in Figure 4 . The piperine-glimepiride group produced a significant increase (p < 0.01) in total antioxidant status Effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride Natural Product Communications Vol. 7 (10) 2012 1285 at all time intervals of the study. This suggests that the combination of these drugs may stimulate the antioxidant mechanisms and interfere with PK and PD.
Finally, piperine affects the metabolism of glimepiride in STZinduced diabetic rats, possibly by the inhibition of CYP2C9. Combination of glimepiride with piperine considerably enhances the glucose-lowering effect of glimepiride. Hence, glimepiride doses may require special attention if used along with piperine containing herbal preparations to avoid complications.
Experimental

Drugs and chemicals:
Glimepiride and gliclazide were obtained as gift samples from Dr Reddy's laboratories (Hyderabad, India). Methanol (HPLC-grade), potassium dihydrogen orthophosphate and orthophosphoric acid of AR grade (99.5%) were procured from Merck Specialties Pvt. Ltd., Mumbai. Piperine, α, α -diphenyl-βpicrylhydrazyl (DPPH) and streptozotocin (STZ) were purchased from HiMedia Laboratories Pvt. Ltd, Mumbai. Merck analytical kits were used to estimate the serum biochemical parameters such as glucose, SGPT, SGOT, total protein, triglycerides and total cholesterol. Water for analytical purpose was double distilled, filtered using direct-Quv millipore and sonicated for removing air bubbles. All other chemicals used were of analytical grade.
Maintenance of animals:
Male albino rats of Wistar strain weighing 180-250g were purchased from Mahaveera Enterprises, Hyderabad, India and used for the studies after obtaining permission from the institutional animal ethical committee (CPCSEA Reg. No.146/1999). The animals were housed in standard polypropylene cages and maintained under standard laboratory conditions (12:12 h light and dark cycle; at an ambient temperature of 25 ± 5 0 C; 35-60% of relative humidity). The animals were fed with standard rat pellet diet and water ad libitum.
Pharmacokinetic study
Grouping of normal rats and pretreatment: Rats were divided into 2 groups (n = 6). Group I was administered with glimepiride (1 mg/kg; b.w., p.o.) suspended in normal saline [15] on the 8 th day. Group II was pretreated with piperine (20 mg/kg; b.w., p.o.) [16] for 7 days and on the 8 th day the rats were administered with glimepiride (1 mg/kg), followed by piperine.
Before the collection of blood samples, animals were fasted for 16 h with water ad libitum. Blood samples were collected by retro-orbital vein puncture [17] using heparinized capillary tubes at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 h. Serum was separated after centrifugation at 8000 rpm for 15 min and stored at -20 0 C until analysis.
Induction of diabetes in rats:
Diabetes was induced by using streptozotocin (55 mg/kg, b.w., i.p.) in citrate buffer (pH 4.5) to the overnight fasted Wistar rats [18] . After 72 h, blood samples were collected from rats by retro orbital puncture and the serum was analyzed for glucose levels. Animals with blood glucose level > 250 mg/dL were considered as diabetic and were used for the study.
Grouping of diabetic rats and treatment:
Diabetic rats were divided into 2 groups (n = 6) and were treated; blood samples were collected as mentioned for normal rats.
HPLC analysis of glimepiride in normal and diabetic pretreated rats:
Serum glimepiride concentration was determined by reverse phase HPLC [15] . The HPLC system was equilibrated with the mobile phase consisting of methanol: 10 mM potassium dihydrogen ortho phosphate (pH 3.0, adjusted with ortho phosphoric acid) (80:20 v/v), at a flow rate of 1.0 mL/min. Serum samples were denatured by methanol and then centrifuged at 8000 rpm for 15 min. Twenty μL of clear supernatant was injected into the HPLC system for quantitation.
Pharmacodynamic studies Assessment of hypoglycemic activity in STZ-induced diabetic rats:
STZ-induced diabetic rats were divided into 4 groups (n = 6). The animals of group I (diabetic control, normal saline), group II (glimepiride, 1 mg/kg), group III (piperine, 20 mg/kg) and group IV [piperine (20 mg/kg) + glimepiride (1 mg/kg)] were treated orally. Blood samples were drawn from the retro-orbital plexus of the rats at '0' (initial fasting blood sample) and 2, 4, 6, 8, 12 and 24 h after treatment. The samples were analyzed for blood glucose using the glucose oxidase-peroxidase method [19] .
Assessment of different biochemical parameters in STZ-induced diabetic rats:
Overnight fasted STZ-induced diabetic rats were divided into 4 groups (I-IV), as mentioned in the antihyperglycemic study, and treated once a day for 28 days (sub acute study) and their body weight, fasting blood glucose, serum insulin, serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), serum cholesterol, serum triglyceride and serum total proteins recorded [20] . During the study period, the body weight of the animals and blood glucose levels were recorded after 7, 14, 21 and 28 days of the treatment. Serum insulin, SGOT, SGPT, serum cholesterol, serum triglyceride and serum total protein levels were estimated after 28 days of treatment.
Estimation of total antioxidant status in diabetic pretreated rats:
The serum samples of the sub acute study were used to determine the total antioxidant status using the DPPH method [21] . A standard graph was prepared using different concentrations of ascorbic acid in water (y = 0.0018 x + 0.0116, r = 0.9953) and the antioxidant status values were expressed in terms of nM of ascorbic acid.
Statistical analysis:
The pharmacokinetic parameters were calculated by using Kinetica TM software (version 4.4.1, Thermo Electron Corporation, USA). All values of the pharmacokinetic and pharmacodynamic studies were expressed as mean ± SD. The data were statistically evaluated using one way analysis of variance (ANOVA) followed by post hoc Dunnet's t -multiple comparison test using Graph Pad Prism 4 computer software.
